Bristol Myers Squibb (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has recommended approval of Opdivo or nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction or GEJ cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy or CRT.
The European Commission, which has the authority to approve medicines for the European Union, will now review the CHMP recommendation.
The positive opinion was based on results from the Phase 3 CheckMate -577 trial which showed that treatment with Opdivo following neoadjuvant CRT and complete surgical resection doubled the primary endpoint of disease-free survival (DFS) compared to placebo in the all-randomized population. The safety profile of Opdivo was consistent with previously reported studies.
Opdivo is approved in the United States for the adjuvant treatment of completely resected esophageal or GEJ cancer with residual pathologic disease in patients who have received neoadjuvant CRT.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.